Seonghae Yoon
Overview
Explore the profile of Seonghae Yoon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
249
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Kim D, Yoon S, Ji S, Yang J, Kim Y, Lee S, et al.
Sci Rep
. 2019 Nov;
9(1):17003.
PMID: 31719650
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
22.
Kim D, Lee D, Han J, Lee J, Cho B, Kang J, et al.
Lung Cancer
. 2019 Aug;
135:66-72.
PMID: 31447004
Objectives: The aim of this phase 1/2 study was to evaluate the safety, tolerability, pharmacokinetics and antitumor activity of olmutinib in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell...
23.
Noh Y, Yoon S, Kim S, Lee K, Jang I
Basic Clin Pharmacol Toxicol
. 2019 May;
125(4):370-381.
PMID: 31125491
The main objective of this phase I trial was to investigate pharmacokinetics (PKs) of olmutinib in three racial subjects. We also evaluate safety/tolerability and a population PK and pharmacogenomic analysis...
24.
Lee H, Yu K, Park S, Yoon S, Onohara M, Ahn Y, et al.
Rheumatology (Oxford)
. 2019 May;
58(11):1976-1984.
PMID: 31056705
Objective: URC102, a novel and potent inhibitor of human uric acid transporter 1 (hURAT1), is currently under clinical development to treat patients with gout. We performed a randomized, double-blind, placebo-controlled,...
25.
Lee S, Yoon S, Chung H, Ji S, Yoon S, Yu K, et al.
J Clin Pharmacol
. 2019 Mar;
59(8):1085-1092.
PMID: 30882914
Ursodeoxycholic acid (UDCA) is a secondary bile acid component used for treating primary biliary cirrhosis. This study evaluated and compared the pharmacokinetic (PK) profiles of UDCA and its conjugates glyco-UDCA...
26.
Lee S, Kim Y, Lee J, Im G, Cho J, Chung J, et al.
Eur J Clin Pharmacol
. 2018 Aug;
74(12):1605-1613.
PMID: 30136102
Purpose: Combination therapy of pregabalin and tramadol is used to treat chronic neuropathic pain; however, the pharmacokinetic (PK) interactions of these drugs has not been studied. This study aimed to...
27.
Kim D, Yoon S, Ji S, Yang J, Kim Y, Lee S, et al.
Sci Rep
. 2018 Aug;
8(1):11874.
PMID: 30089798
Ursodeoxycholic acid (UDCA) is a metabolic by-product of intestinal bacteria, showing hepatoprotective effects. However, its underlying molecular mechanisms remain unclear. The purpose of this study was to elucidate the action...
28.
Sunwoo J, Kim Y, Choi Y, Yu K, Nam H, Cho Y, et al.
Drug Des Devel Ther
. 2018 Jun;
12:1707-1714.
PMID: 29928114
Background: LCB01-0371 is a novel oxazolidinone antibiotic that blocks protein production by binding to bacterial 23S ribosomes. This antibiotic is active against Gram-positive bacteria. This study aimed to evaluate the...
29.
Choi Y, Yoon S, Matsumoto K, Ohta Y, Lee S, Yu K, et al.
Drug Des Devel Ther
. 2018 May;
12:1045-1051.
PMID: 29750017
Introduction: Telaprevir, a reversible selective inhibitor of viral protease and a potential blocker of viral replication, is indicated for the treatment of hepatitis C virus genotype 1 infection. In this...
30.
Shin J, Koh Y, Yoon S, Cho J, Kim D, Lee K, et al.
Cancer Med
. 2018 Mar;
7(5):1814-1823.
PMID: 29577674
Although nilotinib has improved efficacy compared to imatinib, suboptimal response and intolerable adverse events (AEs) limit its effectiveness in many patients with chronic myeloid leukemia in chronic phase (CML-CP). We...